A New Option for Bone Health The U.S. Food and Drug Administration (FDA) has officially approved Degevma (denosumab-adet), a biosimilar medication designed to serve as an interchangeable option for Xgeva. This approval marks a significant development in the landscape of oncology and bone-health supportive care. Understanding Degevma Degevma is a RANK ligand inhibitor. It is…